The effect of coenzyme Q10 in statin myopathy

Neuro Endocrinol Lett. 2012;33 Suppl 2:98-101.

Abstract

Objectives: Statins significantly reduce CV morbidity and mortality. Unfortunately, one of the side effects of statins is myopathy, for which statins cannot be administered in sufficient doses or administered at all. The aim of this study was to demonstrate the effect of coenzyme Q10 in patients with statin myopathy.

Design/setting: Twenty eight patients aged 60.6±10.7 years were monitored (18 women and 10 men) and treated with different types and doses of statin. Muscle weakness and pain was monitored using a scale of one to ten, on which patients expressed the degree of their inconvenience. Examination of muscle problems was performed prior to administration of CQ10 and after 3 and 6 months of dosing. Statistical analysis was performed using Friedman test, Annova and Students t-test.

Results: Pain decreased on average by 53.8% (p<0.0001), muscle weakness by 44.4% (p<0.0001). The CQ10 levels were increased by more than 194% (from 0,903 μg/ml to 2.66 μg/ml; p<0.0001).

Conclusion: After a six-month administration of coenzyme Q10, muscle pain and sensitivity statistically significantly decreased.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cardiovascular Diseases / drug therapy
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Male
  • Middle Aged
  • Muscle Weakness / chemically induced*
  • Muscle Weakness / drug therapy*
  • Musculoskeletal Pain / chemically induced*
  • Musculoskeletal Pain / drug therapy*
  • Patient Satisfaction
  • Treatment Outcome
  • Ubiquinone / administration & dosage
  • Ubiquinone / analogs & derivatives*
  • Vitamins / administration & dosage

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Vitamins
  • Ubiquinone
  • coenzyme Q10